Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.
作者信息
Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Bandello Francesco, Loewenstein Anat, Kuppermann Baruch D
机构信息
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Madhavi Netralaya, Ara, Bihar, India.
出版信息
Eye (Lond). 2024 Jul;38(10):1796-1798. doi: 10.1038/s41433-024-03001-8. Epub 2024 Mar 4.
Abstract
摘要
相似文献
1
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.印度的生物类似药雷珠单抗——3期临床试验设计概述
Eye (Lond). 2024 Jul;38(10):1796-1798. doi: 10.1038/s41433-024-03001-8. Epub 2024 Mar 4.
2
Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.生物类似药 FYB201 对比雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效和安全性。
Ophthalmology. 2022 Jan;129(1):54-63. doi: 10.1016/j.ophtha.2021.04.031. Epub 2021 May 3.
3
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial.雷珠单抗生物类似药QL1205治疗新生血管性年龄相关性黄斑变性的疗效与安全性：一项III期随机试验
Ophthalmol Retina. 2025 Apr;9(4):343-351. doi: 10.1016/j.oret.2024.10.001. Epub 2024 Oct 9.
4
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.雷珠单抗生物类似药与参照雷珠单抗产品治疗新生血管性年龄相关性黄斑变性患者的疗效和安全性：一项随机临床试验。
JAMA Ophthalmol. 2021 Jan 1;139(1):68-76. doi: 10.1001/jamaophthalmol.2020.5053.
5
Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.接受生物类似药CKD-701或对照药雷珠单抗治疗的息肉状脉络膜血管病变患者双眼的视力预后和眼内液变化：一项3期随机临床试验的事后分析
Curr Eye Res. 2024 Jun;49(6):663-670. doi: 10.1080/02713683.2024.2323506. Epub 2024 Mar 7.
6
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.抗血管内皮生长因子生物类似药治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD015804. doi: 10.1002/14651858.CD015804.pub2.
7
Biosimilars for Retinal Diseases: An Update.视网膜疾病的生物类似药：最新进展
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
8
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).雷珠单抗生物类似药（拉珠单抗）与创新型雷珠单抗（雷珠单抗注射液）治疗新生血管性年龄相关性黄斑变性（n-AMD）的疗效和安全性比较（BIRA研究）
Eye (Lond). 2022 May;36(5):1106-1107. doi: 10.1038/s41433-021-01616-9. Epub 2021 Jun 22.
9
Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity.比较贝伐单抗、雷珠单抗和雷珠单抗生物类似药在早产儿视网膜病变中的安全性和有效性。
Eye (Lond). 2025 Jun;39(9):1688-1693. doi: 10.1038/s41433-025-03735-z. Epub 2025 Feb 27.
10
The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.《生物类似药悖论：抗血管内皮生长因子生物类似药如何增加患者和整体医疗保健成本》。
Ophthalmology. 2023 Sep;130(9):966-972. doi: 10.1016/j.ophtha.2023.04.019. Epub 2023 Apr 26.
本文引用的文献
1
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis in patients with neovascular age-related macular degeneration.一项前瞻性、随机、平行分组、双盲、多中心研究，旨在比较鲁宾的雷珠单抗与 Lucentis 在治疗新生血管性年龄相关性黄斑变性患者中的疗效、安全性和免疫原性。
Indian J Ophthalmol. 2022 Aug;70(8):3008-3014. doi: 10.4103/ijo.IJO_2118_21.
2
Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration.新型雷珠单抗生物类似药治疗新生血管性（湿性）年龄相关性黄斑变性的随机、双盲、对照临床研究
Clin Ophthalmol. 2021 Jul 16;15:3087-3095. doi: 10.2147/OPTH.S307746. eCollection 2021.
3
Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect.眼科医生对生物类似药的教育需求：对抗反安慰剂效应。
Eye (Lond). 2020 Jun;34(6):1006-1007. doi: 10.1038/s41433-019-0722-6. Epub 2019 Nov 29.
Zotero 插件